HomeInvestors & MediaNews
- On-site presentation scheduled for 7:30 a.m. on the 14th; recorded version to be released online
Seoul (South Korea) – January 9, 2026, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that its licensing partner for tovecimig, Compass Therapeutics, will deliver a presentation at the JPM Healthcare Conference 2026, taking place from January 12 to 15.
Compass Therapeutics is a Boston-based, clinical-stage biotechnology company in the United States. The company has licensed tovecimig, a bispecific antibody developed by ABL Bio, and is developing it as a treatment for biliary tract cancer. Compass Therapeutics’ presentation will be held on January 14 at 7:30 a.m. and will discuss the development status and business strategies of tovecimig, along with updates on its other pipeline assets. A recorded version of the presentation will also be made available on the Compass Therapeutics website.
ABL Bio CEO Sanghoon Lee stated, “Our partner Compass Therapeutics will be presenting to global pharmaceutical and biotechnology stakeholders, and tovecimig, originally developed by ABL Bio, will be highlighted on the global stage. tovecimig has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and Compass Therapeutics plans to submit a Biologics License Application (BLA) based on Phase 2/3 clinical data. Starting with this presentation, we ask for continued interest in tovecimig throughout the year.”
Tovecimig, originally developed by ABL Bio, is a bispecific antibody that simultaneously blocks the signaling pathways of DLL4 (Delta-like ligand 4) and VEGF-A (Vascular Endothelial Growth Factor-A), both of which play key roles in angiogenesis and tumor vascular formation. Preclinical and clinical evidence supports the hypothesis that concurrent inhibition of DLL4 and VEGF-A yields anticancer efficacy by suppressing tumor growth.
Compass Therapeutics is currently conducting the Phase 2/3 COMPANION-002 clinical trial, which compares a combination therapy of tovecimig and paclitaxel with paclitaxel monotherapy. The company plans to release clinical results from COMPANION-002, including overall survival (OS) and progression-free survival (PFS), in the first half of this year.
About ABL Bio
ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. Clinical projects for 8 pipelines, including ABL301 (SAR446159), ABL001 (tovecimig), ABL111 (givastomig), ABL503 (ragistomig), ABL105 (YH32367), ABL104 (YH32364), ABL103, and ABL202 (CS5001/LCB71), are underway for different indications in various countries, including the United States, China, Australia, and Korea. Following the completion of the Phase 1 clinical trial of ABL301 (SAR446159), Sanofi will conduct the subsequent clinical studies. ABL001 (tovecimig) has received Fast Track designation by the U.S. Food and Drug Administration (FDA). In addition, ABL111 (givastomig), co-developed with NovaBridge, has presented encouraging data from the Phase 1b clinical trial evaluating the triple combination therapy with nivolumab and chemotherapy. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).